Can patients with liver cancer be treated with ivonib?

The U.S. Food and Drug Administration (FDA) has approvedIvosidenib (Ivosidenib) for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate dehydrogenase 1 (id h1)-mutated cholangiocarcinoma (CCA) detected by an FDA-approved test. Ivonib is not suitable for the treatment of liver cancer. Liver cancer is a malignant tumor and is not related to the indications for ivonib. For the treatment of liver cancer, doctors usually choose an appropriate treatment plan based on the patient's specific condition and condition, which may include surgical resection, chemotherapy, radiotherapy, targeted therapy, etc.

A trial in which disease progression occurred after 1-2 systemic treatments for advanced disease. The approval was based on data from the study ClarIDHy, with independently assessed progression-free survival (PFS) as the primary endpoint. The median follow-up was 6.9 months, and the hazard ratio for median progression-free survival (PFS) was 0.37. Overall survival (OS) is a key secondary endpoint. In the final analysis of OS, 70.5% of patients in the placebo group received ivosidenib after disease progression, reporting a HR of 0.79 in the ivosidenib group and a median OS of 10.3 months in the ivosidenib group and 7.5 months in the placebo group.

The original version of ivonib has been launched in China, but it is not covered by medical insurance. The price of domestically sold specifications0.25g*60 tablets per box is as high as 100,000 yuan, while the price of the original American version sold overseas is as high as more than 200,000 yuan per box (the price may fluctuate due to exchange rates). Generic drugs of Ivonib are also sold overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of 250mg*60 tablets produced by a Laos pharmaceutical factory may be more than 6,000 yuan per box (the price may fluctuate due to the exchange rate), and the price is relatively cheap.